Physician profile
Jonathan J Lu
NPI 1891139630
$18,810.62
in general payments reported to CMS, 2019-2025
88 companies · $4,872 in 2025
The $4,872 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $1,714 · 2021: $2,008 · 2022: $2,003 · 2023: $2,822 · 2024: $4,683 · 2025: $4,872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,683.93 |
| Education | $692.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,394.10 | 2021-2025 | Erleada, Rybrevant, Akeega |
| Pfizer INC. | $1,364.47 | 2020-2025 | |
| Amgen INC. | $1,197.76 | 2019-2023 | Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals Lp | $1,141.76 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Celgene Corporation | $852.55 | 2019-2025 | Pomalyst, Reblozyl, Opdivo |
| Astellas Pharma US INC | $829.17 | 2019-2025 | Padcev, Xtandi, Xospata |
| E.R. Squibb & Sons, L.L.C. | $736.88 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $705.19 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $654.96 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $581.74 | 2019-2023 | Adcetris |
| Rigel Pharmaceuticals, INC. | $536.07 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Eisai INC. | $472.91 | 2022-2025 | |
| Tempus Ai, INC | $431.60 | 2024-2025 | Xt Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $390.41 | 2021-2025 | |
| Abbvie INC. | $384.77 | 2020-2025 |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $374.84 | 2020-2025 | Ojjaara, Blenrep |
| Incyte Corporation | $373.13 | 2021-2025 | Monjuvi, Jakafi, Niktimvo |
| Regeneron Healthcare Solutions, INC. | $370.16 | 2019-2025 | Libtayo |
| Sobi, INC | $349.00 | 2022-2025 | |
| Daiichi Sankyo INC. | $326.74 | 2020-2025 | Enhertu |
| Tersera Therapeutics LLC | $261.45 | 2024-2025 | Zoladex, Xermelo, Quzyttir |
| Genzyme Corporation | $260.95 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $257.42 | 2021-2025 | Fotivda |
| Springworks Therapeutics, INC. | $250.49 | 2024-2025 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $219.93 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.51 | 2019-2025 | Gilotrif |
| Taiho Oncology, INC. | $199.77 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $176.61 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Blueprint Medicines Corporation | $175.63 | 2020-2024 | Ayvakit |
| Adaptive Biotechnologies Corporation | $174.05 | 2021-2025 | Clonoseq |
| Sirtex Medical INC | $161.60 | 2023-2025 | Sir-Spheres Microspheres |
| Puma Biotechnology, INC. | $160.42 | 2021-2025 | Nerlynx |
| Lilly USA, LLC | $159.23 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $148.83 | 2022-2025 | Tecentriq, Alecensa, Venclexta |
| Array Biopharma INC | $144.49 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Pharmaessentia USA Corporation | $132.88 | 2023-2025 | Besremi |
| Karyopharm Therapeutics INC. | $127.76 | 2021-2024 | Xpovio |
| Pharmacosmos Therapeutics INC. | $126.92 | 2024-2025 | Monoferric, Cosela |
| Ipsen Biopharmaceuticals, INC | $123.83 | 2019-2025 | Onivyde, Somatuline Depot |
| Stemline Therapeutics INC. | $115.09 | 2024-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $112.45 | 2020-2023 | Imbruvica |
| Deciphera Pharmaceuticals INC. | $111.25 | 2021-2025 | Qinlock, Romvimza |
| Caris Mpi, INC. | $108.88 | 2025 | Mi Cancer Seek |
| Dendreon Pharmaceuticals LLC | $90.17 | 2019-2020 | |
| Emd Serono, INC. | $77.80 | 2024-2025 | |
| Immunocore Limited | $77.52 | 2024-2025 | Kimmtrak |
| Janssen Pharmaceuticals, INC | $77.40 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Spectrum Pharmaceuticals INC. | $72.06 | 2023-2024 | Rolvedon |
| Kite Pharma, INC. | $67.03 | 2024 | Yescarta |
| Recordati_rare_diseases_inc. | $63.82 | 2024-2025 | Sylvant, Enjaymo |
| Morphosys, US INC. | $62.60 | 2023 | Monjuvi |
| Beone Medicines USA, INC. | $58.91 | 2025 | Tevimbra |
| Teva Pharmaceuticals USA, INC. | $55.74 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $53.01 | 2022-2024 | |
| Dova Pharmaceuticals | $50.17 | 2020 | |
| Geron Corporation | $47.88 | 2025 | Rytelo |
| Azurity Pharmaceuticals, INC. | $39.92 | 2025 | Danziten |
| Invivyd INC | $39.11 | 2025 | Pemgarda |
| Beigene USA, INC. | $36.31 | 2020-2024 | Brukinsa |
| Mirati Therapeutics, INC. | $29.60 | 2023-2024 | Krazati |
| Progenics Pharmaceuticals, INC. | $29.22 | 2022 | |
| Agios Pharmaceuticals, INC. | $28.76 | 2024 | Pyrukynd |
| Tolmar, INC. | $28.69 | 2023 | |
| Amag Pharmaceuticals, INC. | $25.96 | 2021 | |
| Mauna Kea Technologies, INC. | $25.30 | 2021 | |
| Cti Biopharma Corp. | $23.73 | 2023 | Vonjo |
| Pharming Healthcare, INC. | $23.71 | 2025 | Ruconest |
| Nuvation Bio INC. | $22.86 | 2025 | Ibtrozi |
| Menarini Silicon Biosystems, INC. | $21.47 | 2024 | |
| Genmab U.S., INC. | $21.20 | 2024 | Tivdak |
| Alnylam Pharmaceuticals INC. | $20.77 | 2023 | Givlaari |
| Secura Bio, INC. | $19.88 | 2024 | Copiktra |
| Amneal Pharmaceuticals LLC | $18.29 | 2025 | Alymsys |
| Alexion Pharmaceuticals, INC. | $18.00 | 2024 | Ultomiris |
| Helsinn Therapeutics (U.S.), INC. | $17.67 | 2021 | |
| Adc Therapeutics America, INC. | $15.63 | 2025 | |
| Exelixis INC. | $14.46 | 2024 | Cabometyx |
| Mylan Institutional INC. | $13.84 | 2020 | |
| Inari Medical, INC. | $13.38 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sumitomo Pharma America, INC. | $13.10 | 2023 | Orgovyx |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$75,969.26 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.